La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Enanta Pharmaceuticals Croissance future
Future contrôle des critères 1/6
Les bénéfices de Enanta Pharmaceuticals devraient diminuer de 0.8% par an tandis que son chiffre d'affaires annuel devrait croître de 18% par an. Le BPA devrait croître de de 5% par an. Le rendement des capitaux propres devrait être -64.2% dans 3 ans.
Informations clés
-0.8%
Taux de croissance des bénéfices
5.0%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 30.3% |
Taux de croissance des recettes | 18.0% |
Rendement futur des capitaux propres | -64.2% |
Couverture par les analystes | Good |
Dernière mise à jour | 06 Aug 2024 |
Mises à jour récentes de la croissance future
Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results
Aug 08Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
May 09Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 12Recent updates
Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results
Aug 08Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%
Jul 24Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Jun 19Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
May 09Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth
Mar 05Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 12Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Aug 13We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed
Feb 24Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade
Feb 08Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term
Nov 25Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?
Oct 25Enanta starts mid-stage trial of EDP-938 for RSV infection
Oct 03Enanta Pharma FQ3 2022 Earnings Preview
Aug 07Enanta potential COVID drug shows safety in healthy people in early-stage trial
Jul 29Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?
Jul 04Enanta: Slow Drip
May 17Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Feb 04Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Nov 25Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
9/30/2026 | 72 | -154 | -230 | N/A | 5 |
9/30/2025 | 74 | -120 | -142 | -100 | 7 |
9/30/2024 | 71 | -112 | -121 | -84 | 7 |
6/30/2024 | 72 | -115 | -100 | -90 | N/A |
3/31/2024 | 73 | -132 | -113 | -107 | N/A |
12/31/2023 | 74 | -138 | -99 | -93 | N/A |
9/30/2023 | 79 | -134 | -112 | -103 | N/A |
6/30/2023 | 81 | -132 | -106 | -97 | N/A |
3/31/2023 | 81 | -125 | -102 | -95 | N/A |
12/31/2022 | 82 | -121 | -112 | -107 | N/A |
9/30/2022 | 86 | -122 | -87 | -85 | N/A |
6/30/2022 | 89 | -120 | -91 | -90 | N/A |
3/31/2022 | 92 | -112 | -91 | -90 | N/A |
12/31/2021 | 93 | -101 | -69 | -68 | N/A |
9/30/2021 | 97 | -79 | -71 | -70 | N/A |
6/30/2021 | 97 | -84 | -65 | -64 | N/A |
3/31/2021 | 94 | -74 | -40 | -39 | N/A |
12/31/2020 | 102 | -58 | -21 | -20 | N/A |
9/30/2020 | 122 | -36 | 6 | 7 | N/A |
6/30/2020 | 150 | 2 | 30 | 31 | N/A |
3/31/2020 | 176 | 24 | 35 | 38 | N/A |
12/31/2019 | 188 | 34 | 48 | 54 | N/A |
9/30/2019 | 205 | 46 | 66 | 71 | N/A |
6/30/2019 | 221 | 65 | 85 | 91 | N/A |
3/31/2019 | 234 | 78 | 88 | 93 | N/A |
12/31/2018 | 238 | 86 | 52 | 55 | N/A |
9/30/2018 | 207 | 72 | 26 | 29 | N/A |
6/30/2018 | 215 | 81 | 56 | 58 | N/A |
3/31/2018 | 166 | 52 | N/A | 49 | N/A |
12/31/2017 | 131 | 34 | N/A | 54 | N/A |
9/30/2017 | 103 | 18 | N/A | 53 | N/A |
6/30/2017 | 40 | -21 | N/A | -7 | N/A |
3/31/2017 | 46 | -13 | N/A | -4 | N/A |
12/31/2016 | 50 | -10 | N/A | 9 | N/A |
9/30/2016 | 88 | 22 | N/A | 36 | N/A |
6/30/2016 | 90 | 29 | N/A | 36 | N/A |
3/31/2016 | 87 | 33 | N/A | 23 | N/A |
12/31/2015 | 132 | 63 | N/A | 112 | N/A |
9/30/2015 | 161 | 79 | N/A | 77 | N/A |
6/30/2015 | 149 | 68 | N/A | 74 | N/A |
3/31/2015 | 180 | 116 | N/A | 123 | N/A |
12/31/2014 | 124 | 82 | N/A | 20 | N/A |
9/30/2014 | 48 | 34 | N/A | 20 | N/A |
6/30/2014 | 46 | 35 | N/A | 23 | N/A |
3/31/2014 | 6 | -19 | N/A | -18 | N/A |
12/31/2013 | 5 | -19 | N/A | -4 | N/A |
9/30/2013 | 32 | -7 | N/A | 11 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ENTA devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: ENTA devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: ENTA devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ENTA ( 18% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ENTA ( 18% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: ENTA devrait être non rentable dans 3 ans.